Sandbox g56: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 13: | Line 13: | ||
{{PBI|Staphylococcus saprophyticus}} | {{PBI|Staphylococcus saprophyticus}} | ||
:* 1. '''Urinary tract infections''' | |||
::* Preferred regimen (1): [[Cephalexin]] 500 mg PO qid | |||
::* Preferred regimen (2): [[Amoxicillin-Clavulanate]] 875/125 mg PO bid | |||
::* Preferred regimen (3): [[TMP-SMX]] 160–800 mg PO bid | |||
::* Alternative regimen: [[Levofloxacin]] 500 mg PO qd | |||
{{PBI|Streptococcus anginosus}} | {{PBI|Streptococcus anginosus}} | ||
Revision as of 03:54, 27 July 2015
- Staphylococcus haemolyticus
Return to Top
-
- Preferred regimen (1): Nafcillin 1–2 g IV q4-6h (maximum 12 g/day)
- Preferred regimen (2): Oxacillin 1–2 g IVq4-6h (maximum 12 g/day)
- Preferred regimen (3): Cefazolin 0.5–2 g IV q6-8h
- Alternative regimen (1): TMP-SMX 4–5 mg/kg IV q6–12h
- Alternative regimen (2): Doxycycline 100–200 mg IV q12-24h
- 2. Methicillin-resistant, Glycopeptide-susceptible strain
- Preferred regimen: Vancomycin 15–20 mg/kg IV q8–12h
- 3. Methicillin-resistant, Glycopeptide-resistant strain
- Preferred regimen (1): Daptomycin 4–6 mg/kg IV q24h
- Preferred regimen (2): Linezolid 600 mg PO/IV q12h
- Staphylococcus saprophyticus
Return to Top
- 1. Urinary tract infections
- Preferred regimen (1): Cephalexin 500 mg PO qid
- Preferred regimen (2): Amoxicillin-Clavulanate 875/125 mg PO bid
- Preferred regimen (3): TMP-SMX 160–800 mg PO bid
- Alternative regimen: Levofloxacin 500 mg PO qd
- Streptococcus anginosus
Return to Top
References
- ↑ Abramowicz, Mark (2011). Handbook of antimicrobial therapy : selected articles from Treatment guidelines with updates from The medical letter. New Rochelle, N.Y: The Medical Letter. ISBN 978-0981527826.
- ↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.